IS6881A - Samsett fjölgilt fjölsykru-próteinbóluefni gegn heilasóttarhnettlu - Google Patents

Samsett fjölgilt fjölsykru-próteinbóluefni gegn heilasóttarhnettlu

Info

Publication number
IS6881A
IS6881A IS6881A IS6881A IS6881A IS 6881 A IS6881 A IS 6881A IS 6881 A IS6881 A IS 6881A IS 6881 A IS6881 A IS 6881A IS 6881 A IS6881 A IS 6881A
Authority
IS
Iceland
Prior art keywords
vaccine against
protein vaccine
polysaccharide protein
against meningitis
polyhydric
Prior art date
Application number
IS6881A
Other languages
English (en)
Icelandic (is)
Inventor
P. Ryall Robert
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23001755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6881(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Publication of IS6881A publication Critical patent/IS6881A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IS6881A 2001-01-23 2003-07-22 Samsett fjölgilt fjölsykru-próteinbóluefni gegn heilasóttarhnettlu IS6881A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26343501P 2001-01-23 2001-01-23
PCT/US2002/001963 WO2002058737A2 (en) 2001-01-23 2002-01-22 Multivalent meningococcal polysaccharide-protein conjugate vaccine

Publications (1)

Publication Number Publication Date
IS6881A true IS6881A (is) 2003-07-22

Family

ID=23001755

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6881A IS6881A (is) 2001-01-23 2003-07-22 Samsett fjölgilt fjölsykru-próteinbóluefni gegn heilasóttarhnettlu

Country Status (38)

Country Link
US (9) US8722062B2 (,)
EP (3) EP2957300B1 (,)
JP (6) JP2005504718A (,)
KR (2) KR100947751B1 (,)
CN (1) CN100556459C (,)
AP (1) AP1897A (,)
AU (2) AU2007216743A1 (,)
BE (3) BE2012C050I2 (,)
BR (1) BRPI0206672B8 (,)
CA (1) CA2435681C (,)
CR (1) CR7035A (,)
CY (2) CY1113072T1 (,)
DK (2) DK1355673T3 (,)
EA (1) EA006947B1 (,)
EC (1) ECSP034701A (,)
ES (3) ES2388848T3 (,)
FR (3) FR12C0072I2 (,)
GE (1) GEP20053691B (,)
HR (1) HRP20030598B1 (,)
HU (2) HU230490B1 (,)
IL (3) IL157060A0 (,)
IS (1) IS6881A (,)
LT (1) LT5177B (,)
LU (1) LU92108I2 (,)
LV (1) LV13128B (,)
MX (2) MXPA03006561A (,)
NO (1) NO20033816L (,)
NZ (2) NZ602682A (,)
OA (1) OA12590A (,)
PL (1) PL226184B1 (,)
PT (2) PT1355673E (,)
RO (1) RO122761B1 (,)
SI (1) SI21352A (,)
TN (1) TNSN03041A1 (,)
UA (1) UA92579C2 (,)
WO (1) WO2002058737A2 (,)
YU (1) YU66103A (,)
ZA (1) ZA200306176B (,)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
YU66103A (sh) 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2014218428B2 (en) * 2001-06-20 2016-08-25 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2004033623A2 (en) * 2002-05-16 2004-04-22 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
BR0316271A (pt) * 2002-11-14 2005-10-11 Inst Finlay Ct De Investigacio Método para a obtenção de preparados vacinais conjugados multivalentes, composição vacinal multivalente e uso da mesma
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
PT2172213E (pt) * 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
CN1787839B (zh) * 2003-03-07 2011-09-28 惠氏控股公司 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
US20050002948A1 (en) * 2003-05-07 2005-01-06 Ryall Robert P. Method of enhanced immunogenicity to meningococcal vaccination
WO2005020964A1 (en) * 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
AU2004251742A1 (en) * 2003-06-23 2005-01-06 Sanofi Pasteur, Inc. Immunization method against Neisseria meningitidis serogroups A and C
WO2005000347A1 (en) * 2003-06-23 2005-01-06 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2885040C (en) * 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
AU2011204789B2 (en) * 2004-04-22 2013-07-11 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
JP5718545B2 (ja) * 2004-04-30 2015-05-13 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 髄膜炎菌結合体ワクチン接種
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
AU2005279821A1 (en) * 2004-08-30 2006-03-09 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0419846D0 (en) * 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
CN101072586A (zh) * 2004-09-21 2007-11-14 圣诺菲·帕斯图尔公司 多价脑膜炎球菌源性多糖－蛋白质缀合物及疫苗
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
PL1896061T3 (pl) 2005-06-27 2020-02-28 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
CN101287488B (zh) 2005-09-01 2013-01-30 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
CA2644724C (en) * 2006-03-17 2016-05-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing complex multivalent immunogenic conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US20080026002A1 (en) * 2006-03-22 2008-01-31 Lisa Danzig Regimens for immunisation with meningococcal conjugates
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2688268A1 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
BRPI0818545A2 (pt) 2007-10-19 2017-07-04 Novartis Ag formulações de vacinais meningocócicas
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
MX2011006648A (es) 2008-12-17 2011-10-14 Novartis Ag Vacunas meningococales que incluyen receptor de hemoglobina.
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
ES2707778T3 (es) * 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
CA2793510A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
DK3831406T3 (da) 2010-08-23 2024-06-17 Wyeth Llc Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
US9057716B2 (en) * 2010-09-04 2015-06-16 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
EP3056212B1 (en) 2010-09-10 2019-04-03 Wyeth LLC Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
RU2014151567A (ru) 2012-05-22 2016-07-10 Новартис Аг Конъюгат менингококка серогруппы х
DK2885007T3 (en) * 2012-08-16 2018-12-03 Pfizer Methods for glycoconjugation and compositions
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
CN105007935A (zh) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 用于保护免于白喉和/或破伤风的缀合物
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
KR20150121265A (ko) * 2013-03-18 2015-10-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 치료 방법
EP3613755A1 (en) 2013-07-11 2020-02-26 Novartis AG Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20170198004A1 (en) 2014-05-24 2017-07-13 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016134275A1 (en) 2015-02-20 2016-08-25 Bayer Healthcare Llc Contrast imaging agent with dissolved gas-evolving fluid
KR20160011136A (ko) 2015-03-25 2016-01-29 한국기계연구원 내식성이 향상된 마그네슘 합금 및 이를 이용하여 제조한 마그네슘 합금 부재의 제조방법
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
LT3397324T (lt) 2015-12-30 2022-10-25 Ascendis Pharma A/S Automatinis injektorius su kasečių laikymo sistema
KR102204927B1 (ko) 2016-07-25 2021-01-19 에스케이바이오사이언스(주) 피막 다당류-단백질 접합 백신의 품질 평가 방법
PH12019500399B1 (en) 2016-09-02 2024-05-15 Sanofi Pasteur Inc Neisseria meningitidis vaccine
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
CN110234658B (zh) 2017-01-31 2024-03-12 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
WO2020055788A1 (en) 2018-09-12 2020-03-19 Bayer Healthcare Llc System for conducting a fluid injection procedure
EP3632465A1 (en) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
US12005110B2 (en) 2019-02-14 2024-06-11 University Of Florida Research Foundation, Incorporated Honeybee commensal Snodgrassella alvi vaccine against pathogenic Neisseriaceae
AU2020355401B2 (en) 2019-09-27 2025-03-27 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110903388B (zh) * 2019-12-03 2024-01-02 兰州生物制品研究所有限责任公司 一种将脑膜炎球菌抗血清去交叉反应的方法
IL293904A (en) 2019-12-17 2022-08-01 9286 3620 Quebec Inc Oral delivery systems based on in situ forming protein/polysaccharide coacervates
KR102610292B1 (ko) 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
IL305313A (en) 2021-02-19 2023-10-01 Sanofi Pasteur Meningococcal b recombinant vaccine
WO2023200704A1 (en) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Protein-saccharide conjugation with sodium cyanoborohydride
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2025034954A1 (en) 2023-08-09 2025-02-13 Bayer Healthcare Llc Noble gas delivery device, cartridge, and triggering system for lung functional and structural imaging

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351761A (en) 1978-05-15 1982-09-28 Research Corporation Purified antigen to test for Neisseria gonorrhoeae antibodies
US4404371A (en) 1981-01-14 1983-09-13 Battelle Memorial Institute Carboxymethylcellulose with carbonate bridges and preparation thereof
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
DE3382737T2 (de) 1982-11-10 1994-05-19 Mitsubishi Heavy Ind Ltd Nickel-Chrom-Legierung.
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
DE3660966D1 (en) 1985-04-17 1988-11-24 Akzo Nv Method of applying a road marking composition
DE3518706A1 (de) 1985-05-24 1986-11-27 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe Verfahren zur herstellung von formkoerpern mit verbesserten, isotropen eigenschaften
US4814276A (en) * 1986-04-25 1989-03-21 Becton, Dickinson And Company Selective medium for growth of neisseria
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
US4963534A (en) 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
JP2631035B2 (ja) * 1991-03-12 1997-07-16 アメリカ合衆国 多糖類−タンパク質複合体
FI940700L (fi) 1991-08-16 1994-02-15 Merck & Co Inc Prosessi lipidiä sisältävän bakteerisen kapsulaarisen polysakkaridin konvertoimiseksi lipidivapaaksi polysakkaridiksi
US5314811A (en) * 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5422427A (en) 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
DK0835663T3 (da) * 1992-05-23 2010-02-01 Glaxosmithkline Biolog Sa Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
WO1994005325A1 (en) * 1992-08-31 1994-03-17 North American Vaccine, Inc. Vaccines against group c neisseria meningitidis
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
NZ311000A (en) 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
CZ288908B6 (cs) 1995-06-23 2001-09-12 Smithkline Beecham Biologicals S. A. Kombinovaná vakcína, tato vakcína ve formě sady, způsob její výroby a její použití
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
KR100593466B1 (ko) * 1997-01-21 2007-04-25 파스퇴르 메리오 세룸 에 박신 다당류-펩타이드접합체
EP0975790B1 (de) 1997-01-24 2004-09-29 Schweiz. Serum-&Impfinstitut Bern Neues verfahren zur isolierung von polysacchariden
US6403306B1 (en) * 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
DE69826851T2 (de) 1997-04-24 2005-02-10 Henry M. Jackson Foundation For The Advancement Of Military Medicine Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
EP2199382A3 (en) 1997-05-28 2010-09-22 Novartis Vaccines and Diagnostics S.r.l. Culture medium with yeast or soy bean extract as aminoacid source and no protein complexes of animal origin
JP2002506448A (ja) * 1997-06-24 2002-02-26 カイロン コーポレイション 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6248570B1 (en) 1997-12-23 2001-06-19 Baxter International, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
DE60011571T2 (de) 1999-02-01 2005-08-18 Eisai Co., Ltd. Verbindungen mit immunologischem adjuvanseffekt
JP2002539273A (ja) * 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
EP2270174A1 (en) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
ES2307553T3 (es) 1999-12-02 2008-12-01 Novartis Vaccines And Diagnostics, Inc. Composiciones y procedimientos para estabilizar moleculas biologicas tras liofilizacion.
US6800455B2 (en) * 2000-03-31 2004-10-05 Scios Inc. Secreted factors
OA12302A (en) 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
YU66103A (sh) 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination

Also Published As

Publication number Publication date
GEP20053691B (en) 2005-12-12
EP2957300B1 (en) 2021-07-14
CY2012030I2 (el) 2016-08-31
US20130216571A1 (en) 2013-08-22
HU230490B1 (hu) 2016-08-29
BE2022C502I2 (,) 2023-04-12
KR100947757B1 (ko) 2010-03-18
US20150174259A1 (en) 2015-06-25
FR22C1001I2 (fr) 2025-02-07
OA12590A (en) 2006-06-08
PT1355673E (pt) 2012-08-31
LU92108I2 (fr) 2013-01-29
IL157060A (en) 2013-04-30
US10143757B2 (en) 2018-12-04
US10617766B2 (en) 2020-04-14
JP2016128526A (ja) 2016-07-14
US20140308311A1 (en) 2014-10-16
BRPI0206672B8 (pt) 2021-05-25
CA2435681C (en) 2011-06-21
US20130224241A1 (en) 2013-08-29
US20130177588A1 (en) 2013-07-11
US20180154010A1 (en) 2018-06-07
DK1355673T3 (da) 2012-09-17
WO2002058737A3 (en) 2003-05-22
US8999354B2 (en) 2015-04-07
JP2005504718A (ja) 2005-02-17
AP1897A (en) 2008-10-10
CA2435681A1 (en) 2002-08-01
CN1610560A (zh) 2005-04-27
JP2014043474A (ja) 2014-03-13
FR12C0072I1 (,) 2013-01-04
CN100556459C (zh) 2009-11-04
EA200300827A1 (ru) 2004-06-24
ES2892316T3 (es) 2022-02-03
US8734813B2 (en) 2014-05-27
FR22C1001I1 (fr) 2022-02-18
US20030068336A1 (en) 2003-04-10
US8741314B2 (en) 2014-06-03
KR20090029857A (ko) 2009-03-23
ECSP034701A (es) 2003-10-28
EP2332581A1 (en) 2011-06-15
PL373710A1 (en) 2005-09-05
FR12C0072I2 (fr) 2013-11-01
PL226184B1 (pl) 2017-06-30
KR20030084913A (ko) 2003-11-01
TNSN03041A1 (en) 2005-12-23
HRP20030598B1 (hr) 2013-05-31
CY1113072T1 (el) 2015-08-05
HUS1600040I1 (hu) 2019-05-28
EP1355673B1 (en) 2012-05-30
CR7035A (es) 2008-11-25
LT2003071A (en) 2004-08-25
SI21352A (sl) 2004-06-30
FR15C0094I2 (fr) 2017-05-19
YU66103A (sh) 2006-05-25
NO20033816D0 (no) 2003-08-27
JP2014043475A (ja) 2014-03-13
AU2010219288A1 (en) 2010-09-23
US8722062B2 (en) 2014-05-13
KR100947751B1 (ko) 2010-03-18
ZA200306176B (en) 2005-03-30
US9844601B2 (en) 2017-12-19
CY2012030I1 (el) 2015-08-05
HUP0302999A3 (en) 2011-05-30
EA006947B1 (ru) 2006-06-30
BR0206672A (pt) 2005-05-10
AP2003002829A0 (en) 2003-09-30
RO122761B1 (ro) 2010-01-29
BE2015C077I2 (,) 2021-02-04
BRPI0206672B1 (pt) 2018-11-06
ES2544979T3 (es) 2015-09-07
EP2957300A2 (en) 2015-12-23
FR15C0094I1 (,) 2016-01-22
EP2332581B1 (en) 2015-07-01
ES2388848T3 (es) 2012-10-19
JP2014065745A (ja) 2014-04-17
US20190060475A1 (en) 2019-02-28
PT2332581E (pt) 2015-10-16
JP5795721B2 (ja) 2015-10-14
EP1355673A2 (en) 2003-10-29
DK2332581T3 (en) 2015-10-05
HUP0302999A2 (hu) 2003-12-29
AU2007216743A1 (en) 2007-10-04
BE2012C050I2 (,) 2021-03-23
IL225522A0 (en) 2013-06-27
LT5177B (lt) 2004-11-25
LU92108I9 (,) 2019-01-15
LV13128B (en) 2004-07-20
US20160000928A1 (en) 2016-01-07
NZ602682A (en) 2014-05-30
HRP20030598A2 (en) 2005-06-30
JP2011140522A (ja) 2011-07-21
US9173955B2 (en) 2015-11-03
IL225522A (en) 2016-04-21
IL157060A0 (en) 2004-02-08
MX341760B (es) 2016-09-02
NO20033816L (no) 2003-09-11
MXPA03006561A (es) 2004-10-15
WO2002058737A2 (en) 2002-08-01
UA92579C2 (ru) 2010-11-25
EP2957300A3 (en) 2016-03-30
NZ622900A (en) 2015-11-27

Similar Documents

Publication Publication Date Title
IS6881A (is) Samsett fjölgilt fjölsykru-próteinbóluefni gegn heilasóttarhnettlu
DE60222056D1 (de) Hebestuhl
DE60239403D1 (de) Elektromechanischer mikrosensor
IS7297A (is) Streptococcis Pneumoniae bóluefni
DE60226425D1 (de) Lösliches rage-protein
DE60214255D1 (de) Schlussstück
ITMI20022297A1 (it) Compressore alternativo
NO20033882L (no) Vaksine
FR2830063B1 (fr) Joint homocinetique
DE60210848D1 (de) Verbinder
DE60227850D1 (de) Verdichter
ITMI20012013A0 (it) Compressore
DE60222900D1 (de) Uv-abschirmende peptid-flavonoid konjugate
DE60220505D1 (de) Haarwaschmittel
ATE427957T1 (de) Echinocandinverfahren
DE60221366D1 (de) Verbinder
NO20034165D0 (no) Forankringshylse
DE60233695D1 (de) Verbinder
NO20032963D0 (no) Peptidforbindelser
DE50213801D1 (de) Gelenk
DE10292227D2 (de) Verdichter
FR2822905B1 (fr) Compresseur alternatif
DE10107471B4 (de) Vitrine
DE50108179D1 (de) Verbinder
DE10292226D2 (de) Verdichter